New radiation schedule aims to cut side effects for thymic cancer patients
NCT ID NCT06189183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with stage II or III thymoma or thymic carcinoma are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (hypofractionated radiotherapy)
What this could lead to
If successful, this could offer a more convenient and less toxic radiation option after surgery for thymic tumors, potentially improving disease control.
What could go wrong
This is a small, single-center phase 2 trial with no control group, so results may not be definitive. Radiation can still cause side effects like lung or heart problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China